Chandra Bhagat Pharma Ltd

Chandra Bhagat Pharma Ltd has received in-principle approval from BSE Limited for a preferential issue of 66,00,000 convertible warrants, convertible into an equal number of equity shares. The issue price is not less than Rs. 44 per share, targeting both promoters and non-promoters. The approval is subject to strict compliance with SEBI regulations, including obtaining undertakings from allottees to prevent intra-day trading before allotment. The company must also ensure robust internal controls and complete post-issue formalities within stipulated timelines.

Chandra Bhagat Pharma Limited has announced the closure of its trading window for all directors, officers, Key Managerial Personnel (KMP), and designated employees. This closure is in accordance with the company's internal code of conduct and SEBI's Prohibition of Insider Trading Regulations, 2015. The trading window will remain closed until 48 hours after the announcement of the financial results for the half-year ending September 30, 2026. All relevant personnel have been duly intimated.

Chandra Bhagat Pharma Ltd has issued a corrigendum to its Annual General Meeting (AGM) notice, originally dated August 6, 2026. The AGM is scheduled for September 1, 2026, at 4:00 PM IST at the company's registered office in Mumbai. The corrigendum clarifies the web link for a compliance certificate related to the proposed preferential issue of 66,00,000 convertible warrants. This certificate, issued by Dilip Swarnkar & Associates, confirms compliance with SEBI (ICDR) Regulations. The corrigendum has been sent to shareholders via email and is available on the BSE website and the company's investor relations page. M/s. Amit Dharmani & Associates will act as the scrutinizer for the AGM.

Chandra Bhagat Pharma Ltd has announced its 23rd Annual General Meeting (AGM) will be held on September 1, 2026, at 4:00 PM IST. The meeting will be conducted via electronic mode. The company has also submitted its Annual Report for the financial year 2025-26, which includes the financial statements, auditor's report, and management discussion and analysis. The Annual Report is available on the company's website and the BSE India website.

Chandra Bhagat Pharma Ltd has submitted its Annual Report for the financial year 2025-26, in compliance with SEBI regulations. The report includes the Notice for the 23rd Annual General Meeting (AGM) scheduled for September 1, 2026, at 4:00 PM IST, to be held via electronic mode. The AGM will take place at their registered office in Matunga, Mumbai. The Annual Report is accessible on the company's website (www.cbcpharma.com) and the BSE India website (www.bseindia.com). The filing also lists the Board of Directors, Key Managerial Personnel, Statutory Auditors, and Secretarial Auditors.

Chandra Bhagat Pharma Limited announced board meeting outcomes including approval to increase authorized share capital from ₹8.5 Cr to ₹15 Cr. The company also plans to issue up to 66,00,000 convertible warrants to promoters and non-promoters at ₹44 each, subject to shareholder approval. The board also approved the Directors' Report for FY26 and the notice for the Annual General Meeting scheduled for September 1, 2026. An independent scrutinizer will be appointed for the AGM.

Chandra Bhagat Pharma Ltd has announced a Board of Directors meeting scheduled for August 5, 2026. The primary agenda items include considering an increase in the authorized share capital and approving a fund-raising proposal. This fund raising may involve the issuance of equity shares or convertible warrants through preferential allotment, subject to shareholder approval and legal compliances. The meeting will also decide on the date for an Extra Ordinary General Meeting (EOGM) to seek shareholder consent for the preferential issue and other related matters. Additionally, the trading window for company securities will be closed from July 30, 2026, until 48 hours after the board meeting concludes, to prevent insider trading.

Chandra Bhagat Pharma Ltd has announced that it is exempt from submitting its Corporate Governance Report for the quarter ended June 30, 2026. This exemption is in accordance with Regulation 15 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company's securities are listed on the SME Exchange, which qualifies it for this exemption. Therefore, the company is not required to comply with specific corporate governance provisions outlined in the SEBI regulations.

Chandra Bhagat Pharma Ltd. announced the approval of its audited financial results for the year ended March 31, 2026, during a board meeting held on May 25, 2026. The audit report, furnished by the statutory auditor, presented an unmodified opinion on the annual financial results. The trading window for company shares will open 48 hours after the announcement of the financial statement.

Chandra Bhagat Pharma Ltd's Board of Directors approved the audited financial results for the year ended March 31, 2026, during their meeting held on May 25, 2026. The audit report, furnished by the statutory auditor, had an unmodified opinion. The trading window for the company's shares will open 48 hours after the announcement of the financial statement.